
Fermenta Biotech Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects an average revenue growth CAGR of about 15% over the next 5-6 years, which is a conservative estimate averaging out spikes from new projects (Page 6).
- The premix plant, expected to be operational by end of calendar year 2022, is anticipated to contribute significantly post-marketing period (Pages 9-10).
- Capacity expansions in vitamin D3 human segment total about 40%, with absorption expected within two years depending on market conditions (Page 14).
- The animal feed segment's utilization is currently low (30-35%) but expected to recover, contributing to growth (Page 6).
- New product launches like vegan D3 and vitamin K1 analogs linked to Sayakha project are in progress but may face delay (Page 14).
- Long-term confidence exists to maintain EBITDA margins at 20-25% with a target of 15% revenue growth while managing product mix and market fluctuations (Pages 11, 17).
See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company mentioned a capex of approximately Rs.35 Crores for the premix plant.
- This capex is expected to be funded by a mix of internal accruals and debt.
- No specific mention of new equity fundraising is found in the transcript.
- Management is cautious about stretching financial bandwidth, indicating measured use of debt.
- There is no discussion of any new or additional fundraises, either debt or equity, beyond this context.
See what Fermenta Biotech management said on order book — free account, 30 seconds.
Capex plans
Yes- Construction of a premix plant in Kullu expected to be completed by the end of calendar year 2022 with an estimated capex of Rs.35 Crores.
- Funding for the premix plant will be a mix of internal accruals and debt.
- Plans to increase capacity at the Sayakha project for vitamin D3, though no final decision on capex has been taken yet.
- Focus on launching Vegan D3 made from vegetable oils, prior to advancing vitamin D3 analogs and K1 products.
- Additional capacity expansions: 25% increase in vitamin D3 human segment capacity recently added, expected to be absorbed over next two years depending on market conditions.
- Overall strategy involves backward integration for cholesterol manufacturing with focus on secure supply of wool grease.
- Cautious approach to financial bandwidth to avoid overstretching with multiple ongoing and planned projects.
Track Fermenta Biotech — get its next earnings analysis in your feed
How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?
Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem